You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,800,461


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,800,461
Title: Modified factor VIII cDNA
Abstract:A modified Factor VIII cDNA is described in which the B-domain of the wild-type Factor VIII cDNA has been deleted and a truncated Factor IX intron 1 has been inserted in one or more locatons of the Factor VIII cDNA. Such modified Factor VIII cDNA may be used for a higher yield production of Factor VIII in vitro as well as in a transfervector for gene therapy.
Inventor(s): Negrier; Claude (Irigny, FR), Plantier; Jean Luc (Grigny, FR)
Assignee: Aventis Behring GmbH (Marburg, DE)
Application Number:09/880,887
Patent Claims:1. A process for the production of Factor VIII protein comprising: a) preparing a modified Factor VIII cDNA wherein said Factor VIII cDNA is modified by deletion of the B-domain encoded sequence and insertion of the truncated Factor IX intron 1 (SEQ ID NO: 9) in one or more splice sites of the Factor VIII cDNA; b) introducing the modified Factor VIII cDNA into a cell; and c) expressing the modified Factor VIII cDNA in said cell to produce Factor VIII protein.

2. A process for the production of Factor VIII protein comprising: a) preparing a modified Factor VIII cDNA wherein said FaCTOR VIII cDNA is nodified by replacement of the B-domain encoded sequence with nucleotides encoding four arginiines and insertion of the truncated Factor IX intron 1 (SEQ ID NO: 9) in one or more splice of the Factor VIII cDNA; b) introducing the modified Factor VIII cDNA into 2 cell; and c) expressing the modified Factor VIII cDNA in said cell to produce Factor VIII protein.

3. The process as claimed in claim 1, wherein at least one insertion site of the truncated Factor IX intron 1 is chosen from Factor VIII intron 1 splice site, Factor VIII intron 12 splice site, and Factor VIII intron 13 splice site.

4. The process as claimed in claim 2, wherein at least one insertion site of the truncated Factor IX intron 1 is chosed from Factor VIII intron 1 splice site, Factor VIII intron 12 splice site, and Factor VIII intron 13 splice site.

Details for Patent 6,800,461

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2019-03-17
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2019-03-17
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2019-03-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.